Exploring Biomarkers for Immune Thrombocytopenia
CHF Grant 02536-MOU: Immunoprofiling to Combat Canine Immune Thrombocytopenia
Publication:
Brooks MB, Goggs R, Frye AH, et al. A prospective cohort study to identify clinical diagnostic and prognostic markers of primary immune thrombocytopenia in dogs. J Vet Intern Med. 2024;1‐13. https://doi.org/10.1111/jvim.16985
What can we learn?
Investigators completed a prospective, multi-institution cohort study to identify clinicopathologic features that differentiate primary from secondary immune thrombocytopenia (ITP). While no biomarkers could definitively differentiate the two forms of this disease, they found that lower platelet counts, D dimer concentrations, and platelet membrane protein expression were more common in primary ITP. Additionally, low hematocrit and high BUN were associated with non-survival.
Conclusion:
Clinicopathologic findings at admission can help differentiate primary from secondary ITP in dogs and identify the most severe cases of primary ITP.
Related Articles
- Unraveling the Causes of Canine Immune-Mediated Hemolytic Anemia (11/20/2020)
- Canine Blood Donation (05/01/2020)
- Genetic Test for Pyruvate Kinase (PK) Deficiency (12/08/2009)
Help Future Generations of Dogs
Participate in canine health research by providing samples or by enrolling in a clinical trial. Samples are needed from healthy dogs and dogs affected by specific diseases.
